Daniel J. Vis
Daniel J. Vis
Netherlands Cancer Institute, Amsterdam, The Netherlands
Patvirtintas el. paštas
A landscape of pharmacogenomic interactions in cancer
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
Assessment of PLSDA cross validation
JA Westerhuis, HCJ Hoefsloot, S Smit, DJ Vis, AK Smilde, EJJ van Velzen, ...
Metabolomics 4, 81-89, 2008
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
SN Ooft, F Weeber, KK Dijkstra, CM McLean, S Kaing, E van Werkhoven, ...
Science translational medicine 11 (513), eaay2574, 2019
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
N van Dijk, A Gil-Jimenez, K Silina, K Hendricksen, LA Smit, JM de Feijter, ...
Nature medicine 26 (12), 1839-1844, 2020
Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality
E Gogola, AA Duarte, JR de Ruiter, WW Wiegant, JA Schmid, R de Bruijn, ...
Cancer cell 33 (6), 1078-1093. e12, 2018
T-profiler: scoring the activity of predefined groups of genes using gene expression data
A Boorsma, BC Foat, D Vis, F Klis, HJ Bussemaker
Nucleic acids research 33 (suppl_2), W592-W595, 2005
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t‐based anti‐cancer drugs
R Planells‐Cases, D Lutter, C Guyader, NM Gerhards, F Ullrich, DA Elger, ...
The EMBO journal 34 (24), 2993-3008, 2015
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ...
Scientific reports 6 (1), 1-13, 2016
Effective drug combinations in breast, colon and pancreatic cancer cells
P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ...
Nature 603 (7899), 166-173, 2022
Genome-wide analysis of yeast stress survival and tolerance acquisition to analyze the central trade-off between growth rate and cellular robustness
A Zakrzewska, G Van Eikenhorst, JEC Burggraaff, DJ Vis, H Hoefsloot, ...
Molecular biology of the cell 22 (22), 4435-4446, 2011
Intra‐and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts
K Kemper, O Krijgsman, P Cornelissen‐Steijger, A Shahrabi, F Weeber, ...
EMBO molecular medicine 7 (9), 1104-1118, 2015
Statistical validation of megavariate effects in ASCA
DJ Vis, JA Westerhuis, AK Smilde, J van der Greef
BMC bioinformatics 8 (1), 1-8, 2007
Dynamic metabolomic data analysis: a tutorial review
AK Smilde, JA Westerhuis, HCJ Hoefsloot, S Bijlsma, CM Rubingh, DJ Vis, ...
Metabolomics 6, 3-17, 2010
Phenotyping tea consumers by nutrikinetic analysis of polyphenolic end-metabolites
EJJ van Velzen, JA Westerhuis, JPM van Duynhoven, FA van Dorsten, ...
Journal of proteome research 8 (7), 3317-3330, 2009
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
Z Xue, DJ Vis, A Bruna, T Sustic, S van Wageningen, AS Batra, ...
Cell research 28 (7), 719-729, 2018
Facilitating a culture of responsible and effective sharing of cancer genome data
LL Siu, M Lawler, D Haussler, BM Knoppers, J Lewin, DJ Vis, RG Liao, ...
Nature medicine 22 (5), 464-471, 2016
TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types
N Aben, DJ Vis, M Michaut, LF Wessels
Bioinformatics 32 (17), i413-i420, 2016
Identification of a druggable pathway controlling glioblastoma invasiveness
N Pencheva, MC de Gooijer, DJ Vis, LFA Wessels, T Würdinger, ...
Cell reports 20 (1), 48-60, 2017
Multilevel models improve precision and speed of IC50 estimates
DJ Vis, L Bombardelli, H Lightfoot, F Iorio, MJ Garnett, LFA Wessels
Pharmacogenomics 17 (7), 691-700, 2016
P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas
H Reis, KE van der Vos, C Niedworok, T Herold, O Módos, A Szendrői, ...
International Journal of Cancer 143 (7), 1764-1773, 2018
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20